Viewing Study NCT01016392

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:50 PM
Ignite Modification Date: 2026-02-02 @ 6:46 AM
Study NCT ID: NCT01016392
Status: COMPLETED
Last Update Posted: 2022-04-15
First Post: 2009-11-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency
Sponsor: BioMarin Pharmaceutical
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Observational post-authorization safety study on Kuvan®. View